Нарлапревир
Проводит АО «Р-Фарм»
Страница компанииЭффективность и безопасность пероральной комбинированной терапии препаратами Нарлапревир/Ритонавир и Даклатасвир у пациентов с хроническим гепатитом С (генотип 1B), не получавших ранее лечение
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/424/2017-08-07/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 150 чел. в стране «Россия».
- Центров в реестре: 6 в 2 городах. Список — ниже на странице.
- Плановая дата окончания (01.2019) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 43 · невключение: 17
Критерии включения
- Subjects who meet all of the following criteria are eligible for participation in the study:
- Are willing and able to provide written informed consent.
- Have confirmed chronic HCV infection as documented by:
- positive anti-HCV antibody (Ab) test or
- positive HCV RNA or
- positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit.
- Have HCV genotype 1b at screening as determined by the Central Laboratory. Any non definitive results must exclude the subject from study participation.
- Minimum HCV-RNA level of ≥10,000 IU at baseline.
- No evidence of cirrhosis; availability at Baseline of at least one of the following tests, negative results:
- Liver biopsy within 2 years of screening showing absence of cirrhosis;
- Fibroscan with a result of ≤ 12.5 kPa within 6 months of baseline/Day1;
- FibroTest score of ≤ 0.48 AND APRI of ≤ 1 performed during screening. In the absence of a definitive diagnosis of the presence or absence of cirrhosis by the above criteria, a liver biopsy was required. Liver biopsy results supersede the results obtained by Fibroscan or FibroTest.
- Have a screening electrocardiogram (ECG) without clinically significant abnormalities (P wave < 0.1 s; PQ interval 0,12-0,2 s; QRS complex 0,06-0,1 s; QT interval 0,35-0,49 s).
- Must have the following laboratory parameters at screening:
- alanine aminotransferase (ALT) ≤ 10 x the upper limit of normal (ULN);
- aspartate aminotransferase (AST) ≤ 10 x ULN;
- Hemoglobin ≥ 12g/dL for male, ≥ 11g/dL for female subjects;
- Platelets ≥ 50,000cells/mm3;
- International normalized ratio (INR) ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR;
- Albumin ≥ 3g/dL;
- Direct bilirubin ≤ 1.5 x ULN;
- Hemoglobin A1c (HbA1c) ≤ 10%;
- Creatinine clearance (CLcr) ≥ 60 mL/min, as calculated by the Cockcroft-Gault equation;
- Have not been treated with any investigational drug or device within 30 days of the screening visit.
- A female subject is eligible to enter the study if it is confirmed that she is:
- Not pregnant or nursing;
- Of non-childbearing potential (i.e., women who have had a hysterectomy, both ovaries removed, or medically documented ovarian failure, or are postmenopausal women >50 years of age with cessation \[for ≥12 months\] of previously occurring menses), or
- Of childbearing potential (i.e., women who had not had a hysterectomy, both ovaries removed, or medically documented ovarian failure). Women ≤ 50 years of age with amenorrhea are considered to be of childbearing potential. These women must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the baseline/Day 1 visit prior to enrollment. They must also agree to one of the following from 3 weeks prior to baseline/Day 1 until 6 months after last dose of the investigational drugs:
- Complete abstinence from intercourse. Periodic abstinence from intercourse (e.g., calendar, ovulation, sympto thermal, post-ovulation methods) is not permitted Or
- Consistent and correct use of 1 of the following methods of birth control listed below in addition to a male partner who correctly uses a condom from the date of screening until 6 months after the last dose of the investigational drugs:
- intrauterine device (IUD) with a failure rate of < 1% per year;
- female barrier method: cervical cap or diaphragm with spermicidal agent;
- tubal sterilization;
- vasectomy in male partner; Women of childbearing potential must not rely on hormone-containing contraceptives as a form of birth control during the study. Female subjects using a hormone-containing contraceptive prior to screening must stop their contraceptive regimen use from the date of screening until 6 months after their last dose of investigational drugs.
- All male study participants must agree to consistently and correctly use a condom, while their female partner agrees to use either 1 of the non hormonal methods of birth control listed above or a hormone-containing contraceptive listed below, from the date of screening until 6 months after their last dose of investigational drugs:
- implants of levonorgestrel;
- injectable progesterone;
- oral contraceptives (either combined or progesterone only);
- contraceptive vaginal ring;
- transdermal contraceptive patch;
- Male subjects must agree to refrain from sperm donation for at least 6 months after the last dose of investigational drugs.
- Are in generally good health as determined by the investigator.
- Are able to comply with the dosing instructions for study drug administration and are able to complete the study schedule of assessments.
Критерии невключения
- Subjects with any of the following are not eligible for participation in the study:
- Had prior exposure to IFN, RBV, or other approved or experimental DAA targeting the HCV.
- Had prior exposure to amiodarone within 24 months before the screening
- Are pregnant or nursing female or male with pregnant female partner.
- Сhronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, cholangitis).
- Are infected with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
- Have history of malignancy diagnosed or treated within 5 years; subjects under evaluation for malignancy are not eligible.
- Have chronic use of systemically administered immunosuppressive agents (e.g., prednisone equivalent > 10 mg/day).
- Have clinically relevant drug or alcohol abuse within 12 months of screening. A positive drug screen must exclude subjects unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by the investigator.
- Have excessive alcohol consumption, defined as more than 3 drinks on any single day and more than 7 drinks per week for females, and > than 4 drinks on any single day and more than 14 drinks per week for males.
- Have history of solid organ transplantation.
- Have history of clinically significant illness or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol by Investigators' opinion.
- Have history of a gastrointestinal disorder (or postoperative condition) that can interfere with the absorption of the study drug.
- Have history of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.
- Usage of any prohibited concomitant medications as described in the protocol (list of drugs with expected drug-drug interactions due to concomitant ritonavir usage)
- Have known hypersensitivity to the study investigational medicinal product, the metabolites, or formulation excipients.
- Chronic HCV genotype 1b-infected participant who has the presence of genetic variants coding for the NS5A-Y93 С/H/N/S and/or L31 F/M/V/I amino acid substitutions at Screening.
Источник: ClinicalTrials.gov, NCT03485846 · запись обновлена в реестре 19 декабря 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 5
- The proportion of patients achieved Sustained Virologic Response (SVR12) — Week 12 of follow-up period
Цель исследования
The purpose of this study is to confirm that combination of Narlaprevir, Ritonavir and Daclatasvir is safe and highly effective regimen in treatment-naїve patients with chronic hepatitis C (HCV) genotype 1b infection.
Области и заболевания
Где проходит
6 центров в 2 городах- ГБУЗ города Москвы «Городская клиническая больница № 24 ДЗМ»
- Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека
- ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Минздрава России
- ФГБУ науки Федеральный исследовательский центр питания, биотехнологии и безопасности пищи
Откуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 424 от 07.08.2017 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03485846 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
clinmarket · № 2038 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.